Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company focused on developing molecular glue degrader (MGD)-based medicines, has announced its participation in the 36th Annual Piper Sandler Healthcare Conference. CEO Markus Warmuth will engage in a fireside chat on December 3, 2024, at 3:30 p.m. ET in New York. The presentation will be available through webcast on the company's website's 'Events' section, with replay access for 30 days post-presentation.
Monte Rosa Therapeutics (Nasdaq: GLUE), una compagnia biotecnologica in fase clinica focalizzata sullo sviluppo di medicinali basati su degrader di collagene molecolare (MGD), ha annunciato la sua partecipazione alla 36ª Conferenza Annuale Piper Sandler sulla Salute. Il CEO Markus Warmuth parteciperà a una conversazione informale il 3 dicembre 2024, alle 15:30 ET a New York. La presentazione sarà disponibile tramite webcast nella sezione 'Eventi' del sito web dell'azienda, con accesso alla registrazione per 30 giorni dopo la presentazione.
Monte Rosa Therapeutics (Nasdaq: GLUE), una compañía biotecnológica en fase clínica centrada en el desarrollo de medicamentos basados en degradadores de pegamento molecular (MGD), ha anunciado su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. El CEO Markus Warmuth participará en una charla al calor de la conversación el 3 de diciembre de 2024, a las 3:30 p.m. ET en Nueva York. La presentación estará disponible a través de un webcast en la sección 'Eventos' del sitio web de la empresa, con acceso a la repetición durante 30 días después de la presentación.
몬테 로사 치료제 (Nasdaq: GLUE)는 분자 접착제 분해 효소(MGD) 기반 의약품 개발에 중점을 둔 임상 단계 생명공학 회사로, 제36회 파이퍼 샌들러 헬스케어 컨퍼런스에 참석한다고 발표했습니다. CEO 마르쿠스 바무스는 2024년 12월 3일 오후 3시 30분(동부 시간) 뉴욕에서 진행되는 대화 형식의 발표에 참여할 예정입니다. 발표는 회사 웹사이트의 '이벤트' 섹션을 통해 웹캐스트로 제공되며, 발표 후 30일 동안 다시 볼 수 있습니다.
Monte Rosa Therapeutics (Nasdaq: GLUE), une entreprise biopharmaceutique en phase clinique spécialisée dans le développement de médecins basés sur des dégrateurs de colle moléculaire (MGD), a annoncé sa participation à la 36e Conférence Annuelle de Santé Piper Sandler. Le PDG Markus Warmuth participera à une discussion informelle le 3 décembre 2024, à 15h30 ET à New York. La présentation sera disponible par webcast dans la section 'Événements' du site web de l'entreprise, avec un accès à la rediffusion pendant 30 jours après la présentation.
Monte Rosa Therapeutics (Nasdaq: GLUE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von auf molekularen Kleberabbauern (MGD) basierenden Medikamenten konzentriert, hat seine Teilnahme an der 36. jährlichen Piper Sandler Gesundheitskonferenz bekannt gegeben. CEO Markus Warmuth wird am 3. Dezember 2024 um 15:30 Uhr ET in New York an einem informellen Gespräch teilnehmen. Die Präsentation wird über ein Webcast im Bereich 'Veranstaltungen' der Unternehmenswebsite verfügbar sein, mit Zugang zur Aufzeichnung für 30 Tage nach der Präsentation.
- None.
- None.
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference in New York, NY on Tuesday, December 3, 2024, at 3:30 p.m. ET.
A webcast of the fireside chat will be accessible via the “Events” section of Monte Rosa’s website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.
Investors
Andrew Funderburk
ir@monterosatx.com
Media
Cory Tromblee, Scient PR
media@monterosatx.com
FAQ
When is Monte Rosa Therapeutics (GLUE) presenting at the Piper Sandler Healthcare Conference 2024?
How can I watch Monte Rosa Therapeutics (GLUE) Piper Sandler Conference presentation?
What type of medicines does Monte Rosa Therapeutics (GLUE) develop?
Who will represent Monte Rosa Therapeutics (GLUE) at the Piper Sandler Healthcare Conference?
